## **Supplementary Figures**





Figure S1. Sunitinib induces higher expression of both ET<sub>A</sub> and ET<sub>B</sub> receptors in aorta: ng of ET-1, ET<sub>A</sub> and ET<sub>B</sub> receptor mRNA reported on ng of 18s RNA in the aorta. Data are expressed as mean  $\pm$  SEM, \*p <0.05 compared to vehicle. *EDN1*: Preproendothelin-1; *EDNRA*: endothelin receptor type A; *EDNRB*: endothelin receptor type B.



**Figure S2 : (A)** Difference treatment – baseline of the percentage of fractional shortening for vehicle (n=9), sunitinib (n=10) and sunitinib+macitentan treated mice (n=8) at week 1 and week 3. **(B)** Difference treatment – baseline of mitral flow deceleration time for vehicle (n=9), sunitinib (n=10) and sunitinib+macitentan treated mice (n=8) at week 1 and week 3. Data are expressed as mean  $\pm$  SEM, \*p <0.05 compared to baseline. FS: fractional shortening.